Skip to main content

Table 3 Phenotypes in CYP2C19 and CYP2D6 and outcome of treatment with cyclophosphamide, thalidomide and bortezomib.

From: No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

Treatment Genotypes
classes
CR + PR
(%)
NC + PD
(%)
P value Duration
of treatment,
months
P value TTF1/TNT2
months
P value OS
months
P value
Cyclophosphamide CYP2C19          
  EM vs. 164 (78) 46 (22) 0.7 NR NR 28.7 0.4 73.9 0.4
  IM + PM 23 (75) 14 (24)     25.1 (0.4) 65.6 (0.5)
Thalidomide CYP2C19          
  EM vs. 78 (62) 48 (38) 0.5 7.4 0.9 10.5 0.6 62.4 0.8
  IM + PM 22 (53) 18 (45)   7.0   7.4   65.6  
Bortezomib CYP2C19          
  EM 36 (73) 13 (27) 0.5 3.8 0.6 8.8 0.9 83.4 0.9
  IM + PM 13 (27) 3 (13) (0.3)   (0.6) 7.8 (0.7) 74.0 (0.9)
  CYP2D6          
  UM + EM 21 (81) 5 (19) 1 4.2 0.8 7.8 0.07 69.7 0.12
  IM + PM 16 (84) 3 (16) (0.9)   (0.9) 11.3 (0.2) 96.1 (0.2)
  1. NR, not relevant; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultra rapid metabolizer;
  2. CR, complete response; PR, partial response; NC, no change; PD, progressive disease. TTF, time-to-treatment failure;
  3. TNT, time-to-next treatment
  4. 1) TTF is used for evaluation of efficacy of treatment with cyclophosphamide
  5. 2) TNT is used for evaluation of efficacy of treatment with thalidomide and bortezomib.
  6. For treatment with cyclophosphamide values in italics are adjusted for prognostic markers: TTF: β2-microglobulin; OS: β2-microglobulin, creatinine and Durie-Salmon stage. At relapse age was a prognostic marker. No influence of age was found for patients treated with thalidomide. For treatment with bortezomib values in italics are adjusted for age at start of relapse treatment and are shown in parentheses.